Open-label simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adults

Clinical Neurology and Neurosurgery

Volumn 107, Issue 3, 2005, Pages 207-213

  Gross, Markus W ^a   Altscher, Riglef ^a   Brandtner, Michael ^b   Haeusser Mischlich, Harald ^c   Chiricuta, Ion C ^d   Siegmann, Alessandra D ^e   Engenhart Cabillic, Rita ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b City Hospital   (Germany)

^c Fulda University Hospital   (Germany)

^d City Hospital   (Germany)

^e HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Glioblastoma; Quality of life; Radio chemotherapy; Survival; Topoisomerase inhibition; Topotecan; Toxicity

Indexed keywords

TOPOTECAN;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; BIOPSY; BURSITIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ESOPHAGITIS; FEMALE; GLIOBLASTOMA; HISTOLOGY; HUMAN; INFECTION COMPLICATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; PNEUMONIA; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE; SEPSIS; STATISTICAL SIGNIFICANCE; STUPOR; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREMOR;

EID: 17044380180     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2004.07.016     Document Type: Article

References (41)

1. M.D. Walker, E. Alexander, W.E. Hunt, C.S. MacCarty, M.S. Mahaley, and J. Mealey Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas J. Neurosurg. 49 1978 333 343
2. C.F. Hess, J.C. Schaaf, R.D. Kortmann, M. Schabet, and M. Bamberg Malignant glioma: patterns of failure following individually tailored limited volume irradiation Radiother. Oncol. 30 1994 146 149
3. H.A. Fine, K.B. Dear, J.S. Loeffler, P.M. Black, and G.P. Canellos Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults Cancer 71 1993 2585 2597
4. A.Y. Chen, C. Yu, M. Potmesil, M.E. Wall, M.C. Wani, and L.F. Liu Camptothecin overcomes MDR-1-mediated resistance in human KB carcinoma cells Cancer Res. 51 1992 6039 6044
5. A.Y. Chen, and L.F. Liu DNA topoisomerases: essential enzymes and lethal targets Ann. Rev. Pharmacol. Toxicol. 34 1994 191 218
6. G.G. Grabenbauer, M. Buchfelder, U. Schrell, R. Fahlbusch, R. Sauer, and H.J. Staab Topotecan as a 21-day continuous infusion with accelerated 3d-conformal radiation therapy for patients with glioblastoma T. Wiegel W. Hinkelbein M. Brock T. Hoell Controversies in Neuro-Oncology. Frontiers of Radiation Therapy and Oncology 1999 Karger Basel 364 368
7. D. Macdonald, G. Cairncross, D. Stewart, P. Forsyth, C. Sawka, N. Wainman, and E. Eisenhauer Phase II study of topotecan in patients with recurrent malignant glioma Ann. Oncol. 7 1996 205 207
8. T.A. Rich, and A.V. Kirichenko Camptothecin radiation sensitization: mechanisms, schedules and timing Oncology 12 Suppl 6 1998 114 120
9. R. Sauer, and Heuser A Topoisomerase-I-Inhibitor mit potentiell strahlensensibilisierender Wirkung Strahlenther Onkol. 173 1997 125 130
10. R.E. Boscia, T. Korbut, S.A. Holden, G. Ara, and B.A. Teicher Interaction of topoisomerase I inhibitors with radiation in cis- diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo Int. J. Cancer 53 1993 118 123
11. J.H. Kim, S.H. Kim, A. Kolozsvary, and M.S. Khil Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor or DNA topoisomerase I Int. J. Radiat. Oncol. Biol. Phys. 22 1992 515 518
12. J.P. Lamond, M.P. Mehta, and Boothman DA The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation J. Neurooncol. 30 1996 1 6
13. J.P. Lamond, M. Wang, T.J. Kinsella, and D.A. Boothman Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation Int. J. Radiat. Oncol. Biol. Phys. 36 1996 361 368
14. J.P. Lamond, M. Wang, T.J. Kinsella, and D.A. Boothman Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase inhibitors Int. J. Radiat. Oncol. Biol. Phys. 36 1996 369 376
15. S.M. Blaney, P.C. Phillips, R.J. Packer, R.L. Heideman, S.L. Berg, and P.C. Adamson Phase II evaluation of topotecan for pediatric central nervous system tumours Cancer 78 1996 527 531
16. International commission on radiation units and measurements, ICRU: Report 50 prescribing, recording, and reporting photon beam therapy. Bethesda, 1993.
17. M.H. Seegenschmiedt, and R. Sauer Systematik der akuten und chronischen Strahlenfolgen Strahlenther Onkol. 83 1993 83 95
18. W.J. Curran, C.B. Scott, J. Horton, J.S. Nelson, A.S. Weinstein, and A.J. Fischbach Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials J. Natl. Cancer Inst. 85 1993 704 710
19. ®) Strahlenther Onkol. 177 2001 656 661
20. O. Lang, E. Liebermeister, J. Liesegang, and M.L. Sautter-Bihl Radiotherapy of glioblastoma multiforme. Feasibility of increased fraction size and shortened overall treatment Strahlenther Onkol. 174 1998 629 632
21. O.M. Salazar, P. Rubin, M.L. Feldstein, and R. Pizzutiello High dose radiation therapy in the treatment of malignant gliomas: final report Int. J. Radiat. Oncol. Biol. Phys. 5 1979 1733 1740
22. M. Werner-Wasik, C.B. Scott, D.F. Nelson, L.E. Gaspar, K.J. Murray, and J.A. Fischbach Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. RTOG study 83-02 Cancer 77 1996 1535 1543
23. V. Massey, and Wallner KE Patterns of second recurrence of malignant astrocytomas Int. J. Radiat. Oncol. Biol. Phys. 18 1990 395 398
24. S.D. Baker, R.L. Heideman, W.R. Crom, J.F. Kuttesch, A. Gajjar, and C.F. Stewart Cerebrospinal fluid and penetration of continuous infusion topotecan in children with central nervous system tumours Cancer Chemother. Pharmacol. 37 1996 195 202
25. C.F. Stewart, S.D. Baker, R.L. Heideman, D. Jones, W.R. Crom, and C.B. Pratt Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts haematological toxicity J. Clin. Oncol. 12 1994 1946 1954
26. C.S. Straathof, M.J. van den Bent, W.J. Loos, C.J. Vecht, and J.H. Schellens The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration J. Neurooncol. 42 1999 117 122
27. J.P. Lamond, R. Kirwin, M.E. Wall, and D.A. Boothman Topoisomerase I inhibitors potentiate radiation lethality in vitro Proc. Am. Assoc. Cancer Res. 36 1995 441
28. M. Tronconi, R. Supino, R. Marchesini, P. Perego, A. Colombo, and F. Zunino Interaction of topotecan with ionizing radiation in two human tumour cell lines Proc. Am. Assoc. Cancer Res. 36 1995 612
29. Cairncross G Topotecan for recurrent malignant glioma: long times to tumour progression may indicate efficacy J. Neurooncol. 30 1996 163
30. H.S. Friedman, T. Kerby, S. Fields, J.E. Zilisch, D. Graden, and R.E. McLendon Topotecan treatment of adults with primary malignant glioma Cancer 85 1999 1160 1165
31. R.P. Kadota, C.F. Stewart, M. Horn, J.F. Kuttesch, P.C. Burger, and J.L. Kepner Topotecan for the treatment of recurrent or progressive central nervous system tumours - a pediatric oncology group phase II study J. Neurooncol. 43 1999 43 47
32. P.A. Burch, A.M. Bernath, T.L. Cascino, B.W. Scheithauer, P. Novotny, and S. Nair A North Central cancer treatment group phase II trial of topotecan in relapsed gliomas Invest. New Drugs 18 2000 275 280
33. B. Fisher, M. Won, D. Macdonald, D.W. Johnson, and W. Roa Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of radiation therapy oncology group 9513 Int. J. Radiat. Oncol. Biol. Phys. 53 2002 980 986
34. F. Schmidt, M. Schuster, and J. Streffer Topotecan-based combination chemotherapy for human malignant glioma Anticancer Res. 19 1999 1217 1221
35. B. Fisher, C. Scott, and D. MacDonald Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507 J. Clin. Oncol. 19 2001 1111 1117
36. R. Stupp, P.Y. Dietrich, and S. Ostermann Kraljevic Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide J. Clin. Oncol. 20 2002 1375 1382
37. M. Weller, B. Müller, and R. Koch Neuro-oncology Working Group of the German Cancer Society. Neuro-oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma J. Clin. Oncol. 21 2003 3276 3284
38. F. Wuerschmidt, H. Buenemann, and H.P. Heilmann Prognostic factors in high-grade malignant glioma Strahlenther Onkol. 171 1995 315 321
39. F.W. Kreth, BerlisA, and V. Spiropoulou The role of tumour resection in the treatment of glioblastoma multiforme in adults Cancer 86 1999 2117 2123
40. F.K. Albert, M. Forsting, and K. Sartor Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis Neurosurgery 34 1994 45 61
41. F.G. Barker, M.D. Prados, and S.M. Chang Radiation response and survival time in patients with glioblastoma multiforme J. Neurosurg. 84 1996 442 448